Gastric cancers arise through a multistep process characterized by the progressive accumulation of molecular alterations in which genetic and epigenetic mechanisms have been implicated. Gastric cancer is one of the human malignancies in which aberrant promoter CpG island hypermethylation is frequently found. Helicobacter pylori and Epstein-Barr virus, which are known carcinogens for gastric cancer, are closely associated with enhanced hypermethylation of CpG island loci in gastric non-neoplastic epithelial cells and cancer cells, respectively. Aberrant CpG island hypermethylation occurs early in the multistep cascade of gastric carcinogenesis and tends to increase with the step-wise progression of the lesion. Approximately 400 genes that are actively expressed in normal gastric epithelial cells are estimated to be inactivated in gastric cancers as a result of promoter CpG island hypermethylation. In this review, a variety of information is summarized regarding CpG island hypermethylation in gastric cancer.
1
The field of epigenetics describes information transmission through cell division of heritable changes in a phenotype that does not involve DNA sequence changes. CpG island hyper methylation, histone modification, and transmitted chromatin structure are the underlying mechanisms for epigenetic trans mission, and CpG island hypermethylation is a key component for altered gene expression associated with human cancers. CpG islands are DNA segments that are at least 0.5 kb in size, rich in G:C and CpG content, and found in approximately 70% of human gene promoters. 1 Promoter CpG islands are usually un methylated in normal cells, with the exception of those on an inactive X chromosome or associated with imprinted genes. Although the cause is unclear, promoter CpG island hyperme thylation can occur in association with cancer development and aging. Promoter CpG island hypermethylation is found in vir tually all human cancer tissue types and acts as an important mechanism for the inactivation of tumor suppressor genes and tumorrelated genes. 2, 3 Gastric cancer is one of the human can cers in which promoter CpG island hypermethylation is fre quently found. 2, 4 In our preliminary study, which analyzed 41 candidate genes in major types of human cancers and canceras sociated normal tissues, gastric cancer demonstrated a signifi cantly higher number of methylated genes than those of other human cancer tissue types (Fig. 1 ). In addition, gastric cancer associated normal mucosa also exhibited the highest number of methylated genes when compared to normal tissue from other organs, including the lung, breast, colon, and liver ( Fig. 1) . These facts suggest the possibility that aberrant CpG island hyperme thylation is more involved in the carcinogenesis of gastric can cer than in that of other human cancer tissue types.
GASTRIC CANCER METHYLATION CHANGE
How many genes are known to be methylated in gastric cancer?
In 1996, Lee et al. 5 reported for the first time that p16 was inactivated in gastric cancer by promoter CpG island hyper methylation rather than by genetic mutation. Since then, many researchers have demonstrated cancerspecific hypermethylation and inactivation of candidate genes in gastric cancer tissues and have correlated this hypermethylation with clinicopathologic features. However, the number of genes demonstrated to be in activated by promoter CpG island hypermethylation was limit ed until the application of arraybased genomescale DNA me thylation analysis for gastric cancers. With the application of 5aza2´deoxycytidine (DAC) treatment and oligonucleotide microarrays, Yamashita et al. 6 estimated that approximately 421 genes are silenced by promoter CpG island hypermethylation in a gastric cancer cell line (AGS). Considering the fact that pro moter CpG island hypermethylation is exaggerated in a cancer cell line compared with primary cancer tissue and that the AGS cell line has an increased rate of de novo methylation because of overexpression of DNMT3b, the actual number of genes silenc ed by promoter CpG island hypermethylation can be estimated to be less than 421 in primary gastric cancers. Our team also performed bead arraybased expression analysis of gastric cancer cell lines before and after DAC treatment with subsequent con firmation of CpG island hypermethylation of the candidate genes by methylationspecific PCR. We found 140 novel genes that are silenced by promoter CpG island hypermethylation in pri mary gastric cancer tissue (Jung et al. in preparation).
The timing of hypermethylation in multistep gastric carcinogenesis
Promoter CpG island hypermethylation is now recognized to be an important mechanism responsible for the inactivation of tumor suppressor genes or tumorrelated genes. If promoter CpG island hypermethylation of some genes plays an important role in the malignant transformation of gastric epithelial cells, this pattern of hypermethylation should be found in premalignant lesions of the stomach, including gastric adenomas and intesti nal metaplasia. In order to determine the frequency and timing of hypermethylation during multistep gastric carcinogenesis, Kang et al. analyzed multistep lesions of the stomach, in regards to their methylation status, in five genes 7 or 12 genes 8 using me thylationspecific PCR or in 25 genes using MethyLight analy sis; 9 they demonstrated that promoter CpG island hypermeth ylation occurs early in multistep gastric carcinogenesis and ac cumulates during progression of the gastric lesion along the mul tistep carcinogenesis pathway. During multistep gastric carci nogenesis, there is a steep rise in the number of methylated genes when progressing from chronic gastritis to intestinal metapla sia, which was a consistent finding in a series of studies. 79 Re gardless of the status of Helicobacter pylori infection, the number of methylated genes in intestinal metaplasia was significantly higher than that found in chronic gastritis without intestinal metaplasia. 9 This suggests that intestinal metaplasia is an epi genetically altered lesion. However, even in chronic gastritis with out intestinal metaplasia, promoter CpG island hypermethyl ation occurs in association with H. pylori infection 10 and aging.
11,12
Helicobacter pylori infection-associated DNA hypermethylation H. pylori has been designated as a human class I carcinogen for gastric malignancy by the International Agency for Research on Cancer. Although the exact mechanism of H. pyloriassociat ed gastric carcinogenesis is unknown, longstanding bacterial infection, perpetuated chronic inflammation, and sustained mu cosal epithelial cell proliferation are thought to produce a carci nogenic environment. Chan et al. 10 were the first to demonstrate H. pyloriassociated hypermethylation in the gastric epithelia, which was supported by subsequent studies demonstrating that the eradication of H. pylori infection results in a reversal of the methylation status of multiple CpG island loci. 1315 Thus, it is plausible that aberrant methylation induced by H. pylori infec tion may contribute to H. pylori infectionassociated gastric car No. of methylated genes
cinogenesis. It has been reported that interleukin 1 beta can mo dulate CpG island methylation through the activation of DNA methyltransferase. 16 In an in vitro study, interleukin 1 beta siR NA blocked H. pyloriinduced methylation of the CDH1 pro moter CpG island locus in a gastric cancer cell line. 17 In an ani mal model experiment by the Ushijima team, H. pylori infec tion resulted in the induction of CpG island hypermethylation of candidate genes, and the eradication led to marked decreases in methylation levels in the candidate genes. However, the sup pression of inflammation by treatment with the immunosup pressive drug cyclosporine blocked the induction of DNA me thylation in the candidate genes. These findings suggest that the infectionassociated inflammatory response, rather than H. pylori itself, was responsible for the induction of altered DNA methylation. 18 In a subsequent gerbil study, neutrophilic infla mmation caused by treatment with ethanol or NaCl did not in duce DNA methylation in candidate genes, whereas chronic in flammation caused by H. pylori or H. felis infection led to alter ed methylation in candidate genes. This finding suggests that it is not the inflammation itself, but rather specific types of in flammation, that are necessary for methylation induction. 19 
Aging-related hypermethylation vs inflammation-related hypermethylation
Challenging traditional thought regarding the lack of CpG island methylation in normal tissues, a recent study indicated that 48% of CpG island loci are methylated in the genomic DNA of human blood, brain, muscle, and spleen tissue. 20, 21 Ad ditionally, normal cells have been shown to acquire hypermeth ylation in an agingrelated manner: agingrelated methylation was first demonstrated for the oestrogen receptor (ER) gene by Issa et al. 22 and has subsequently been demonstrated in multiple genes by Ahuja et al. 23 In the stomach, Waki et al. 11 reported agingrelated methylation of CDH1, MLH1, and p16 in non neoplastic gastric epithelia. However, because CpG island hy permethylation can be induced by chronic inflammation in the stomach and because the prevalence of H. pylori infection in creases with age, 24 the interplay between aging and chronic in flammation is complicated by H. pylori infection. Chan et al. 25 found that CDH1 methylation was associated with age in the stomach, the presence of chronic gastritis, and H. pylori infec tion using a univariate analysis, but H. pylori infection was the only independent factor associated with CDH1 methylation in the multivariate analysis. Furthermore, Maekita et al. 26 reported that there was no agingrelated hypermethylation in healthy gastric mucosa. However, a current study by our team supports the presence of agingrelated hypermethylation in the gastric mucosa because the number of methylated genes was signifi cantly higher in H. pylorinegative adult stomach samples than in H. pylorinegative pediatric samples. 27 In WI38 human em bryonic lung fibroblasts, p16 was found to undergo spontaneous promoter CpG island hypermethylation during passage of these cells in culture, 28 which supports the presence of agerelated hy permethylation. Thus, we cannot exclude the possibility that agingrelated methylation occurs in nonneoplastic gastric epi thelia without H. pylori infection.
Field cancerization
Many studies have shown that methylation levels or frequen cies of multiple genes are higher in gastric mucosa from gastric cancer patients than in mucosa from noncancer subjects. 11, 26, 29 In a stomach with enhanced CpG island hypermethylation, the affected cells may have a growthselective advantage imparted by the expressional loss of the methylated genes, which may predispose the cells to acquiring further genetic or epigenetic defects that lead to neoplasia. Synchronous multiple gastric cancers, constituting 49% of gastric cancers, occur at an older age and are more commonly associated with an extensive distri bution of intestinal metaplasia in the background mucosa com pared with single gastric cancer. 30, 31 In a recent study, nonneo plastic gastric mucosa from synchronous gastric cancer patients was found to have more hypermethylated genes than nonneo plastic gastric mucosa from patients with a single gastric cancer, which suggests that enhanced hypermethylation in the back ground gastric mucosa might contribute to the development of multiple gastric cancers. 32 Multiple gastric cancers are not only a genetic model but also an epigenetic model for field cancer ization. Based on the findings that methylation levels in gastric mucosa are significantly increased in cases with a single gastric cancer and even more so in cases with multiple gastric cancers, it has been suggested that quantitative information regarding methylation levels of specific genes may serve as a biomarker for predicting an individual's risk for developing gastric cancer. 32, 33 However, it should be noted that increased methylation levels or frequencies in gastric mucosa from gastric cancer patients may reflect a higher prevalence of H. pylori infection and intes tinal metaplasia (compared with gastric mucosa from noncan cer subjects). 34, 35 Because both H. pylori infection and intestinal metaplasia are closely linked with increased CpG island hyper methylation, further clarification is needed regarding whether nonneoplastic gastric mucosa without intestinal metaplasia from H. pylorinegative gastric cancer patients harbors more hy permethylated genes than nonneoplastic gastric mucosa from H. pylorinegative noncancer subjects. In Park et al.'s study, 9 no significant differences were observed in the number of methyl ated genes or methylation levels of 25 individual genes in chron ic gastritis tissue from cancer and noncancer patients after nor malization of the confounding factors of H. pylori and intestinal metaplasia. Because synchronous multiple gastric cancers tend to be associated with widespread intestinal metaplasia when com pared with single gastric cancers, cancerassociated gastric mu cosa might show higher methylation frequencies or higher me thylation levels of multiple CpG island loci in multiple synch ronous gastric cancer patients than in single gastric cancer pa tients.
Prognostic implications of individual gene methylation
Promoter CpG island hypermethylation can be utilized as a tumor biomarker for the detection of tumor cells in gastric juice or serum or for the prediction of clinical outcomes. A dozen DNA methylation markers have been reported to be closely as sociated with worse or better clinical outcomes in gastric cancer patients; MAL or COX2 methylation was correlated with better clinical outcomes in gastric cancer patients, 36, 37 whereas DAPK, TMS1, IQGAP2, SOX2, CACNA2D3, DKK-3, TFPI2, and Cystatin methylation has been correlated with worse clinical outcomes in gastric cancer patients. 3844 However, most of the studies that have evaluated these DNA methylation markers for their prognostic implication used methylationspecific poly merase chain reaction (MSP). Although MSP is a highly sensi tive method for detecting one methylated allele in 10,000 un methylated alleles, 45 it is unreliable for detecting low levels of methylation. Another issue related to these DNA methylation markers is that a validation study was not performed to prove their utility as a prognostic marker. The final issue concerns concordance among individual gene hypermethylation: hyper methylation of one specific gene tends to be concordant with that of another individual gene; thus, better or worse survival observed in gastric cancers with hypermethylation of an indi vidual gene may not be attributed to hypermethylation of that particular gene. Rather, survival may be related to concordant hypermethylation of multiple CpG island loci, namely CpG is land methylator phenotype (CIMP).
CIMP-positive gastric cancer
CIMP refers to a subset of malignancies that is characterized by widespread hypermethylation of multiple promoter CpG is land loci. Since the CIMP concept was first introduced for the molecular pathways of colorectal cancers (CRCs) by Dr. Issa's group, 46 many investigators have attempted to characterize the clinicopathological and molecular features of CIMPpositive CRCs and have found a close association with proximal colon location, older age at onset, poor differentiation, microsatellite instability (MSI), and BRAF mutations. 4749 Similarly, the pres ence of CIMPpositive gastric cancers has been reported by the same group, 50 which did not find distinct clinicopathologic fea tures of CIMPpositive gastric cancers, with the exception of a close association with MSI. Since then, several researchers have attempted to characterize the clinicopathological features of CIMPpositive gastric cancers using variable methodologies for DNA methylation analysis and their own CIMP marker panels; this has led to controversial results. 5156 Despite variable find ings, relatively common findings include close associations of CIMPpositive gastric cancers with diffuse typehistology and better clinical outcomes. Recently, with the exclusion of MSI positive gastric cancers and EpsteinBarr virus (EBV)positive gastric cancers from the analysis, Park et al. 57 found characteris tic clinicopathologic features of CIMPpositive gastric cancers that were defined as tumors with methylation of 13 or more markers during the analysis of the 16 cancerspecific DNA me thylation markers; these defined CIMPpositive gastric cancers tended to show distinct clinicopathologic features, including a proclivity toward diffuse or mixedtype histology, poor differ entiation, infiltrative gross types, and higher cancer stages.
EBV-associated gastric cancer
In addition to H. pylori, EBV has also been recognized as a gastric cancercausing infectious agent. 58, 59 EBVassociated gas tric cancer, comprising nearly 10% of gastric cancers, are char acterized by a younger age at onset, male predominance, proxi mal location, frequent association of lymphoid stroma, and a better prognosis. 60 EBVassociated gastric cancer is a prototype of the CIMPpositive types of gastric cancer and exhibits con sistently higher frequencies and levels of methylation in exam ined cancerrelated methylation markers, 53, 57, 61 which is inde pendent of whether the EBVassociated gastric cancer is histo logically lymphoepitheliomalike or ordinary. 60 Because the number of methylated cancerspecific methylation markers is far higher in EBVassociated gastric cancers than in EBVnega tive gastric cancers, EBVassociated aberrant hypermethylation is a global event. However, MLH1 methylation and resultant MSI are, if ever, rarely observed in EBVassociated gastric can cers. Although it can be speculated that the methylation ma chinery of EBVassociated gastric cancer is capable of recogniz ing its own methylation targets, it may be hypothesized that the presence of both CIMP and MSI could cause a growth dis advantage and subsequently lead to the negative selection of gastric cancer cells containing both CIMP and MSI. Tumor cells from EBVassociated gastric cancers display DNA methyltransferase I overexpression, 62 which is closely associated with interleukin-1-beta (IL1B) overexpression 60 or latent membrane protein 2Aassociated phosphorylation of signal transducer and activator of transcription 3 (STAT3) in EBVassociated gastric cancers.
63
IL1B is capable of increasing the expression of DNMT1 via the production of nitric oxide, and phosphorylated STAT3 binds to the DNMT1 promoter and induces transcription.
MSI-positive gastric cancer
The frequency of MSIpositive gastric cancer varies from 8% to 37%. In gastric cancer, MSI is mainly caused by promoter CpG island hypermethylation of the MLH1 gene. Somatic mu tations of mismatch repair genes are very rare in sporadic gastric cancers. Thus, known clinicopathological features of MSIposi tive gastric cancer, including female sex, older age of onset, an tral location, ulcerofungating gross type by Borrmann's classifi cation, intestinal type by Lauren classification, expanding type by Ming classification, and better survival 64 represent features of sporadic MSIpositive gastric cancer. Since gastric cancer is an extracolonic lesion in Lynch syndrome, we have encountered MSIpositive gastric cancer without MLH1 methylation. Re cently, our team has compared clinicopathological features be tween MSIpositive gastric cancers with and without MLH1 methylation (Kim et al. in preparation) . Of the known clinico pathological features for MSIpositive gastric cancer, female pre ponderance, older age of onset and antral location do not corre spond with Lynch syndromeassociated MSIpositive gastric cancer. 65 Several studies have shown that MLH1 methylation occurs in premalignant stages, including intestinal metaplasia and gastric adenoma. Thus, MLH1 methylation has been con sidered an early event during multistep gastric carcinogene sis. 7, 9, 66, 67 However, a recent study of Ling et al. 68 has shown that MSI can develop from MSIlow or the absence of MSI due to timedependent accumulation of DNA methylation during progression of early stagegastric cancer, which indicates that silencing of MLH1 due to promoter hypermethylation may ap pear as a later event during multistep gastric carcinogenesis. Unfortunately, the study did not investigate whether later ac quisition of MLH1 methylation occurs as a phenomenon of CIMP. MLH1 methylation is unlikely to occur as an isolated sporadic event without concurrent hypermethylation of multi ple gene promoter CpG island loci. 78 In particular, Ando et al. 77 demonstrated that miR-124a-1, -2, and -3 are frequently meth ylated in primary gastric cancer and in normal gastric mucosal tissues from healthy individuals with H. pylori infections. Among H. pylorinegative individuals, methylation levels are significant ly higher in noncancerous gastric mucosal tissues from gastric cancer patients than gastric mucosal tissues from healthy indi viduals, which suggest that methylation of miRNA genes com prises a field defect contributing to the pathogenesis of gastric cancer. 77 Suzuki et al. 78 also reported that miR-34b/c methylation is significantly associated with H. pylori infection among healthy individuals.
Future perspective
Although it is well known that EBVpositive gastric cancer is featured with extensive hypermethylation of multiple genes, the mechanism leading to genomewide hypermethylation is still unknown. Because EBVpositive gastric dysplasia or ade noma has never been reported, it seems likely that EBVinfected epithelial cells transform directly into malignant cells. DNMT1 elevation in association with EBV infection does not provide a satisfactory explanation for genomewide extensive hypermeth ylation because in vitro transfection of DNMT1 in cell lines or DNMT1 elevation in association with H. pylori infection also does not lead to such extensive hypermethylation as seen in EBV positive gastric cancer. If we can elucidate the mechanism of EBVassociated extensive hypermethylation, we will have a bet ter understanding of how promoter CpG island hypermethyl ation occurs.
Although gastric cancer has shown a higher number of genes methylated compared with colorectal cancer, clinicopathologi cal features of CIMPpositive gastric cancer are still obscure and marker panels diagnosing CIMPpositive gastric cancer are not established yet, which is in contrast to the situation in colorec tal cancer. It is imperative to develop CIMP panel markers en abling the diagnosis of CIMPpositive gastric cancer and then to characterize clinicopathological features of CIMPpositive gastric cancer. In case these are accomplished, we expect to iden tify the precursor lesions of CIMPpositive gastric cancer and to delineate multistep morphological progression of CIMPposi tive tumors.
CONCLUSION
Although molecular pathways and morphological pathways are not well established for gastric cancers when compared with colorectal cancers, rapid development of methylation analysis technology will enable us to take a glimpse at the landscape of epigenetic alterations occurring at each step of multistep gastric carcinogenesis, which will provide molecular insights on mor phological progression pathways. In addition, epigenetic stud ies may offer great potential for the identification of tumor bio markers that can be utilized to detect and diagnose gastric can cer at its earliest stages, to accurately assess an individual's risk for gastric cancer, or to predict the response to chemotherapy or clinical outcomes.
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